ArticlePloS one2017

First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery.

Norbert Pfeiffer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.